Human monoclonal antibody Fab fragments directed against HCV...

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S133100, C424S141100, C424S147100, C530S387100, C530S387300, C530S388100, C530S388300

Reexamination Certificate

active

07727529

ABSTRACT:
The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines.

REFERENCES:
patent: 7091324 (2006-08-01), Foung et al.
patent: WO 00/05266 (2000-02-01), None
patent: WO 02/005560 (2002-07-01), None
Burioni et al., “Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant fab fragments,” vol. 28 No. 3, pp. 810-814 (Sep. 1998).
Habersetzer et al., “Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties,” Virology, vol. 249 No. 1, pp. 32-41 (Sep. 1998).
Poul et al., “Design of cassette baculovirus vectors for the production of therapeutic antibodies in insect cells,” Immunotechnology, vol. 1 No. 3-4, pp. 189-196 (Dec. 1995).
Bretner, Maria, Existing and future therapeutic options for hepatitis C virus infection, Acta Biochimica polonica, vol. 52 No. 1, pp. 57-70 (2005).
Leroux-Roels, Geert, Development of prophylactic and therapeutic vaccines against hepatitis C virus, Expert Review of Vaccines, vol. 4 No. 3, pp. 351-371 (Jun. 2005).
Perotti et al., “Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein,” Journal of Virology, vol. 82 No. 2, pp. 1047-1052 (Jan. 2008).
Eren et al., “Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment to Prevent HCV Reinfection in Liver Transplant Patients,” Journal of Virology, vol. 80 No. 6, pp. 2654-2664 (Mar. 2006).
Bugli et al., “Mapping B-Cell Epitopes of Hepatitis C Virus E2 Glycoprotein Using Human Monoclonal Antibodies from Phage Display Libraries,” Journal of Virology, vol. 75 No. 20, pp. 9986-9990 ( Oct. 2001).
PCT International Search Report for Burioni, Roberto, Int'l Application No. PCT/IT03/00032, Filed Jan. 29, 2003, Dated Aug. 6, 2003.
Allander, et al., “Recombinant Human Monoclonal Antibodies against Different Conformational Epitopes of the E2 Envelope Glycoprotein of Hepatitis C Virus That Inhibit Its Interaction with CD81.” Journal of General Virology, vol. 81, 2451-2459 (2000).
Burioni, et al., “Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs.” Virology, vol. 288, 29-30 (2001).
Dietzschold et al., “Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system”, Proc. Natl. Acad. Sci., USA, vol. 89, pp. 7252-7256 (1992).
Fujinami et al, “Survival of Athymic (nu
u) Mice after Theiler's Murine Encephalomyelitis Virus Infection by Passive Administration of Neutralizing Monoclonal Antibody”, Journal of Virology, vol. 63, No. 5, pp. 2081-2087 (1989).
Lavillette et al., “Human Serum Facilitates Hepatitis C Virus Infection, and Neutralizing Responses Inversely Correlate with Viral Replication Kinetics at the Acute Phase of Hepatitis C Virus Infection”, Journal of Virology, vol. 79, No. 10, pp. 6023-6034 (2004).
Law et al., “Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge”, Nature Publishing Group, pp. 1-3 (2007).
Logvinoff et al., “Neutralizing antibody response during acute and chronic hepatitis C virus infection”, PNAS, vol. 101, No. 27, pp. 10149-10154 (2004).
Moore et al., “HIV-1 neutralizing antibodies: How fill is the bottle”, Nature America Inc, vol. 5, No. 2, pp. 142-144, (1999).
Rosa D., et al., “A Quantitative Test to Estimate Neutralizing Antibodies to the Hepatitis C Virus: Cytofluorimentric Assessment of the Envelope Glycoprotien 2 Binding to Target Cell.” Proceedings of the National Academy of Sciences of USA, National Academy of Science. Washington, US, vol. 93, No. 3 (Mar. 1, 1996).
Virgin et al., “Antibody Protects against Lethal Infection with the Neurally Spreading Reovirus Type 3 (Dearing)”, Journal of Virology, vol. 62, No. 12, pp. 4594-4604 (1988).
Wohlfart, Claes, “Neutralization of Adenoviruses: Kinetics, Stoichiometry, and Mechanisms”, Journal of Virology, vol. 62, No. 7, pp. 2321-2328 (1988).
U.S Office Action for Burioni., U.S. Appl. No. 10/502,307, filed Jul. 22, 2004, Dated Mar. 2, 2007.
U.S Office Action for Burioni., U.S. Appl. No. 10/502,307, filed Jul. 22, 2004, Dated Apr. 30, 2008.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Human monoclonal antibody Fab fragments directed against HCV... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human monoclonal antibody Fab fragments directed against HCV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibody Fab fragments directed against HCV... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4237625

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.